National Commander Wiley praises president's order that will expedite psychedelic treatments for mental health, offering relief to GWOT veterans and others dealing with PTSD, TBIs and other invisible wounds of war.
President Donald Trump signed an executive order April 18 aimed at accelerating research and improving access to emerging therapies, including certain psychedelic treatments for mental health conditions affecting veterans.
The American Legion has long-supported, evidence-based research into innovative treatments for conditions such as PTSD, traumatic brain injury, chronic pain and severe depression; issues that continue to affect many who served, particularly those from the Global War on Terrorism.
"Thanks to the advancements of research, there is hope that these psychedelic drugs will serve as a pathway to and promise of a brighter future for our veterans and their loved ones," said American Legion National Commander Dan K. Wiley. "We must ensure that any treatment brought forward is grounded in sound science, proven safe and accessible through the Department of Veterans Affairs when appropriate."
Last October, The American Legion approved Resolution 13 that calls for further research on the safety and efficacy of emerging therapies, including psilocybin, ibogaine root, lysergic acid diethylamide, 5MeO-DMT, cannabis and MDMA to treat PTSD, TBI and other ailments in veterans and their partners.
- Veterans Healthcare